A phase I study of oral UFT given concomitantly with standard preoperative radiotherapy for rectal cancer

被引:0
|
作者
Pfeffer, MR [1 ]
Kundel, Y
Zehavi, M
Catane, R
Koller, M
Zmora, O
Elkayam, R
Symon, Z
机构
[1] Chaim Sheba Med Ctr, Oncol Inst, Radiat Oncol Unit, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Dept Surg, IL-52621 Tel Hashomer, Israel
来源
ISRAEL MEDICAL ASSOCIATION JOURNAL | 2004年 / 6卷 / 10期
关键词
rectal cancer; preoperative radiotherapy; UF7; chemoradiation; phase I trial;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Preoperative radiotherapy is standard treatment for rectal cancer and is often combined with 5-fluorouracil-based chemotherapy. UFT, a new oral 5FU derivative, given daily during a course of radiotherapy mimics the effect of continuous-infusion 5FU. Objectives: To determine the maximum tolerated dose of oral UFT and leucovorin with preoperative pelvic irradiation for rectal cancer, and assess tumor response. Methods: In this phase 1 trial, 16 patients aged 42-79 years with tumors within 12 cm of the anal verge received radiotherapy, 45 Gy over 5 weeks, an escalating dose of oral UFT, and a fixed dose of 30 mg/day leucovorin. UFT and leucovorin were given for 28 consecutive days concomitant with the first 4 weeks of radiotherapy. Surgery was scheduled for 4-6 weeks after completion of radiotherapy. The surgical procedure was determined by the surgeon at the time of surgery. Results: No grade III toxicity was seen at 200 mg/m(2)/day UFT. Of eight patients who received 240 mg/m(2)/day LIFT, one developed grade IV diarrhea; of four patients who received 270 mg/m(2)/day UFT, one was hospitalized with grade IV diarrhea and leukopenic fever and died during hospitalization. Of the 15 evaluable patients, 9 had pathologic tumor downstaging including 4 patients with complete response. Only one patient required a colostomy. Conclusions: The MTD of UFT together with leucovorin and preoperative radiotherapy for rectal cancer is 240 mg/m(2). The major toxicity was diarrhea. Downstaging was noted in 60% of patients, allowing sphincter-preserving surgery even in patients with low tumors.
引用
收藏
页码:595 / 598
页数:4
相关论文
共 50 条
  • [21] PREOPERATIVE RADIOTHERAPY IN RECTAL CANCER
    DUNCAN, W
    SMITH, AN
    LANCET, 1976, 2 (7981): : 364 - 365
  • [22] A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer
    Ngan, SYK
    Michael, M
    Mackay, J
    McKendrick, J
    Leong, T
    Joon, DL
    Zalcberg, JR
    BRITISH JOURNAL OF CANCER, 2004, 91 (06) : 1019 - 1024
  • [23] A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer
    S Y K Ngan
    M Michael
    J Mackay
    J McKendrick
    T Leong
    D Lim Joon
    J R Zalcberg
    British Journal of Cancer, 2004, 91 : 1019 - 1024
  • [24] Phase I trial of oral topotecan (OT) and radiotherapy (XRT) in rectal cancer (RCA).
    Yeatman, T
    Lima, CMR
    Barthel, J
    Calvin, D
    Garret, C
    Dinwoodie, WR
    Mayfield, S
    Wright, M
    Lush, R
    Sullivan, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 304S - 304S
  • [25] A PHASE II STUDY OF CONCURRENT PREOPERATIVE CHEMOTHERAPY AND RADIOTHERAPY ON LOCALLY ADVANCED RECTAL CANCER
    Khalaf, Marwa
    Eid, Samir
    Hamza, Hesham
    ANNALS OF ONCOLOGY, 2012, 23 : 111 - 111
  • [26] Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
    Braendengen, Morten
    Tveit, Kjell M.
    Berglund, Ake
    Birkemeyer, Elke
    Frykholm, Gunilla
    Pahlman, Lars
    Wiig, Johan N.
    Bystrom, Per
    Bujko, Krzysztof
    Glimelius, Bengt
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3687 - 3694
  • [27] Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer
    Freedman, Gary M.
    Meropol, Neal J.
    Sigurdson, Elin R.
    Hoffman, John
    Callahan, Elaine
    Price, Robert
    Cheng, Jonathan
    Cohen, Steve
    Lewis, Nancy
    Watkins-Bruner, Deborah
    Rogatko, Andre
    Konski, Andre
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (05): : 1389 - 1393
  • [28] Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer
    de la Torre, A
    Ramos, S
    Valcárcel, FJ
    Candal, A
    Regueiro, CA
    Romero, J
    Magallón, R
    Salinas, J
    de las Heras, M
    Veiras, C
    Tisaire, JL
    Aragón, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (03): : 629 - 634
  • [29] Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer
    de, la Torre, Alejandro
    Ramos, Salvador
    Valcarcel, Francisco J.
    Candal, Arturo
    Regueiro, Carlos A.
    Romero, Jesus
    Magallon, Rosa
    Salinas, Juan
    de las Heras, Manuel
    Veiras, Camilo
    Tisaire, Jose L.
    Aragon, Gregorio
    International Journal of Radiation Oncology, Biology, Physics, 45 (03): : 629 - 634
  • [30] PINCH is an independent prognostic factor in rectal cancer patients without preoperative radiotherapy: A study in a Swedish rectal cancer trial of preoperative radiotherapy
    Holmqvist, Annica Elisabet
    Holmlund, Birgitta
    Ardsby, Malin
    Gao, Jingfang
    Adell, Gunnar
    Johansson, Ann-Charlotte
    Carstensen, John
    Langford, Dianne
    Sun, Xiao-Feng
    CANCER RESEARCH, 2012, 72